NA

The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid repl...

The present invention it relates to an thiopheneacetamide compound characterized by the following formula (III): wherein Y represents a leaving group

A process for preparing a compounds represented by Formula (I), whrein R1 represents strangth -chain or branched C1-5 alkyl, C1-5 haloalkyl,or C3-8 cycloalkyl and R represents C1-3 alkyl or haloalkyl.

Disclosed herein is a secondary battery having a mechanical connection sensor, as a safety device, fixed to the outer surface of a prismatic or pouch-shaped battery cell while the mechanical connection sensor is set to OFF. The mechanical connection sensor is connected in series with a resistor having a predetermine...

A lipophilic microparticle having an average particle size ranging from 0.1 to 200 µm, comprising a lipophilic substance and an active ingredient selected from the group consisting of a protein or peptide drug and an antigen, retains the full activity of the active ingredient, and when formulated in the form of an o...

A process for preparing a compound represented by formula (I), wherein R1 represents straight-chain or branched C1-5 alkyl, Cl-5 haloalkyl, or C3-6 cycloalkyl, and R2 represents C1-3 alkyl or C1-3 haloalkyl.

A process for purifying hepatitis B viral surface antigen comprising the preS2 peptide from the cells of a recombinant organism, which is characterized in that said cells are disrupted using a buffer containing a chaotropic salt.

A sustained-release drug composition comprises microparticles of hyaluronic acid or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 µm.

The present invention relates to a process for preparing a protected 4-aminomethyl-pyrrolidin-3-one represented by the following formula (1) which is an essential intermediate for the preparation of quinolone antibiotics. wherein P1 and P2 independently of one another represent acetyl, t-butoxycarbonyl or pivalo...

This invention relates to a process for the preparation of an analgesic composition comprising morphine and nimodipine dissolved in a solution containing polyethylene glycol.

NOT ENTERED AT PRESENT TO BE ENTERED LATER

A process for preparing solid microparticles having an average sizeranging from 0.1 to 40µM of hyaluronic acid or an inorganic salt thereof having encased therein protein or peptide drugs such as herein described, the process comprising the steps of : (1) preparing an aqueous solution containing the pr...

7-(3-aminomethyl-4-methoxyiminopyrrolidin-l-yl)-l-cyclopropyl-6-fiuoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxy lie acid methanesulf-onate and hydrates thereof, processes for their preparation, pharmaceutical and veterinary compositions comprising them, and their use in ant...